MLIP Antikörper (C-Term)
Kurzübersicht für MLIP Antikörper (C-Term) (ABIN1450122)
Target
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- C-Term
-
Kreuzreaktivität (Details)
- Species reactivity (tested):Human.
-
Aufreinigung
- Affinity chromatography purified via peptide column
-
Immunogen
- 16 amino acid synthetic peptide near the carboxy terminus of Human MLIP
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1.0 mg/mL
-
Buffer
- PBS containing 0.02 % Sodium Azide as preservative
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freezing and thawing.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- MLIP (Muscular LMNA-Interacting Protein (MLIP))
-
Andere Bezeichnung
- MLIP
-
Hintergrund
- The muscle-enriched A-type lamin-interacting protein (MLIP) is ubiquitously expressed, although most predominantly in heart, skeletal and smooth muscle, and interacts directly and co-localizes with lamin A and C in the nuclear envelope. MLIP also co-localizes with promyelocytic leukemia (PML) bodies within the nucleus. Decreasing lamin A/C expression with siRNA results in the upregulation and mislocalization of MLIP, suggesting that MLIP localization to the nuclear envelope is dependent on the lamin proteins. It has been suggested that MLIP may function as a tethering protein linking LMNA to factors within the nuclear envelope of within PML bodiesSynonyms: C6orf142, Muscle enriched A-type lamin interacting protein
-
Gen-ID
- 90523
-
NCBI Accession
- NP_612636
Target
-